• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[Enzalutamide vs active surveillance in patients with low-risk prostate cancer].

作者信息

Dunst Jürgen, Krug David

机构信息

Klinik für Strahlentherapie Kiel, UKSH, Kiel, Deutschland.

出版信息

Strahlenther Onkol. 2023 Feb;199(2):201-203. doi: 10.1007/s00066-022-02015-z. Epub 2022 Oct 19.

DOI:10.1007/s00066-022-02015-z
PMID:36260108
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9877082/
Abstract
摘要

相似文献

1
[Enzalutamide vs active surveillance in patients with low-risk prostate cancer].恩杂鲁胺与低风险前列腺癌患者主动监测的对比
Strahlenther Onkol. 2023 Feb;199(2):201-203. doi: 10.1007/s00066-022-02015-z. Epub 2022 Oct 19.
2
Re: Active Surveillance Plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial.回复：低风险或中风险局限性前列腺癌患者中主动监测联合恩杂鲁胺单药治疗与单纯主动监测的比较：ENACT随机临床试验
Eur Urol. 2022 Nov;82(5):572. doi: 10.1016/j.eururo.2022.07.030. Epub 2022 Aug 9.
3
Active surveillance versus enzalutamide for low-risk prostate cancer - was it really a trial we needed?主动监测与恩杂鲁胺治疗低风险前列腺癌——这真的是我们需要的试验吗？
BJU Int. 2022 Nov;130(5):580-581. doi: 10.1111/bju.15860. Epub 2022 Aug 2.
4
Enzalutamide With Radiation Therapy for Intermediate-Risk Prostate Cancer: A Phase 2 Study.恩杂鲁胺联合放射治疗中危前列腺癌：一项 2 期研究。
Int J Radiat Oncol Biol Phys. 2021 Aug 1;110(5):1416-1422. doi: 10.1016/j.ijrobp.2021.02.027. Epub 2021 Feb 23.
5
Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration Resistant Prostate Cancer in the TERRAIN Trial.在TERRAIN试验中恩杂鲁胺与比卡鲁胺治疗年轻和老年转移性去势抵抗性前列腺癌患者的疗效与安全性
J Urol. 2018 Jan;199(1):147-154. doi: 10.1016/j.juro.2017.08.080. Epub 2017 Aug 19.
6
Phototoxic eruption caused by enzalutamide (Xtandi).恩杂鲁胺（安可坦）引起的光毒性皮疹。
Contact Dermatitis. 2021 Jan;84(1):64-65. doi: 10.1111/cod.13692. Epub 2020 Sep 18.
7
Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.恩杂鲁胺对比比卡鲁胺用于去势抵抗性前列腺癌：STRIVE 试验。
J Clin Oncol. 2016 Jun 20;34(18):2098-106. doi: 10.1200/JCO.2015.64.9285. Epub 2016 Jan 25.
8
A European, prospective, observational study of enzalutamide in patients with metastatic castration-resistant prostate cancer: PREMISE.一项关于转移性去势抵抗性前列腺癌患者恩扎卢胺的欧洲、前瞻性、观察性研究：PREMISE。
Int J Cancer. 2022 Mar 1;150(5):837-846. doi: 10.1002/ijc.33845. Epub 2021 Nov 8.
9
Effectiveness of first-line abiraterone versus enzalutamide among patients ≥80 years of age with metastatic castration-resistant prostate cancer: A retrospective propensity score-weighted comparative cohort study.一线阿比特龙与恩杂鲁胺治疗≥80 岁转移性去势抵抗性前列腺癌患者的疗效：一项回顾性倾向评分加权比较队列研究。
Eur J Cancer. 2021 Jul;152:215-222. doi: 10.1016/j.ejca.2021.05.003. Epub 2021 Jun 12.
10
Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.达罗他胺对比阿帕他胺和恩扎卢胺用于去势抵抗性前列腺癌的间接比较。
J Urol. 2021 Aug;206(2):298-307. doi: 10.1097/JU.0000000000001767. Epub 2021 Apr 5.

本文引用的文献

1
To Treat or Not to Treat Men With Low-risk or Intermediate-risk Prostate Cancer-Weighing the Evidence.治疗还是不治疗低风险或中风险前列腺癌男性——权衡证据
JAMA Oncol. 2022 Aug 1;8(8):1137-1138. doi: 10.1001/jamaoncol.2022.1623.
2
Enzalutamide Monotherapy vs Active Surveillance in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial.恩杂鲁胺单药治疗与主动监测在低危或中危局限性前列腺癌患者中的比较：ENACT 随机临床试验。
JAMA Oncol. 2022 Aug 1;8(8):1128-1136. doi: 10.1001/jamaoncol.2022.1641.
3
Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer.局部前列腺癌主动监测、手术、近距离放疗或外照射放疗联合或不联合雄激素剥夺治疗 5 年的患者报告结局。
JAMA. 2020 Jan 14;323(2):149-163. doi: 10.1001/jama.2019.20675.
4
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.恩扎卢胺联合标准一线治疗转移性前列腺癌。
N Engl J Med. 2019 Jul 11;381(2):121-131. doi: 10.1056/NEJMoa1903835. Epub 2019 Jun 2.
5
Neoadjuvant Enzalutamide Prior to Prostatectomy.前列腺切除术前新辅助恩杂鲁胺治疗
Clin Cancer Res. 2017 May 1;23(9):2169-2176. doi: 10.1158/1078-0432.CCR-16-1357. Epub 2016 Nov 9.
6
Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial.度他雄胺在局限性前列腺癌管理中的应用：REDEEM 随机、双盲、安慰剂对照试验。
Lancet. 2012 Mar 24;379(9821):1103-11. doi: 10.1016/S0140-6736(11)61619-X. Epub 2012 Jan 24.
7
Systematic review of early vs deferred hormonal treatment of locally advanced prostate cancer: a meta-analysis of randomized controlled trials.
BJU Int. 2007 Jun;99(6):1383-9. doi: 10.1111/j.1464-410X.2007.06802.x. Epub 2007 Mar 6.
8
Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up.比卡鲁胺（康士得）150毫克联合早期非转移性前列腺癌的标准治疗：前列腺癌早期试验24在中位7年随访期的结果。
Prostate Cancer Prostatic Dis. 2007;10(1):87-93. doi: 10.1038/sj.pcan.4500916. Epub 2006 Nov 14.
9
Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.晚期前列腺癌治疗中早期与延迟雄激素抑制疗法的比较
Cochrane Database Syst Rev. 2002(1):CD003506. doi: 10.1002/14651858.CD003506.